Khondrion

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Khondrion sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting later-stage tilt upper half by trial count

Khondrion: 1 sponsored US clinical trial, 1 recruiting.

Khondrion sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, with 1 trials.

Mid-pack sponsor footprint

Khondrion is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Where Khondrion enrollment is open (later-stage tilt)

1 recruiting of 1 indexed (100% open).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Khondrion: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Khondrion sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Khondrion1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Khondrion sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Khondrion sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Khondrion page

1 registered trials is a research-attention snapshot, not an endorsement of Khondrion or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Khondrion pipeline card: 1 registered trials from official public datasets.Report a data error.